Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Nicholas C. Richardson
FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma
Oncologist
Cancer Research
Medicine
Oncology
Related publications
Our First Experiences With Brentuximab Vedotin in the Treatment of Cutaneous T-Cell Lymphoma
Bőrgyógyászati és Venerológiai Szemle
Redefining the Role of Etoposide in First-Line Treatment of Peripheral T-Cell Lymphoma
Blood advances
Hematology
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma
Clinical Cancer Research
Cancer Research
Oncology
Effects of First-Line Chemotherapy on Natural Killer Cells in Adult T-Cell Leukemia–lymphoma and Peripheral T-Cell Lymphoma
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma
OncoTargets and Therapy
Oncology
Pharmacology
Brentuximab-Vedotin and Bendamustine Is a Feasible and Effective Drug Combination as First-Line Treatment of Hodgkin Lymphoma in the Elderly (Halo Trial)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
First Salvage Treatment With Bendamustine and Brentuximab Vedotin in Hodgkin Lymphoma: A Phase 2 Study of Fil Onlus
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Polatuzumab Vedotin: First Global Approval
Drugs
Pharmacology
Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
